Urinary biomarkers precede loss of kidney function for lupus nephritis In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation. https://t.co/MJb9F3uEgr https://t.co/oXvNLelE89

Less (Glucocorticoids) is More in Lupus Nephritis Dr. Yuz Yusof talks with Dr. Amir Saxena about abstract 0781 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/EriaJvBPj9 https://t.co/x5hNIAgBz2

Difficult toTreat PsA: Mainly Difficult to Define! Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/vXDY47xWfS https://t.co/l5hJFc7blH

Psoriatic Arthritis Topic Panel https://t.co/I3puVr5HWa https://t.co/sCzjnnDG1G

Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology The top ACR2023 Plenary abstracts Dr. Dao ( @kdao2011) found impactful for her practice were... https://t.co/aXut7l7b79 https://t.co/ATO5r5OzGK

ACR23 – Day 3 Report F2F learning amidst miles of research and many young talented aside wizened establish presenters is such a welcome return to ACR, the way it should be. https://t.co/TwmwfEQZdp https://t.co/Yo27c7ig8N

Watch: Lupus Nephritis Therapy Paradigm Shift Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/poIVX74EnO https://t.co/tWlRlwTfH0

IV Secukinumab for AxSpa The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis. https://t.co/eDAWevPLkE https://t.co/AlWYGAQP5T

Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI

How early is early in psoriatic arthritis? Is there a window of opportunity for treatment in PsA to ensure optimal outcomes? https://t.co/SHA8Gdm1GD https://t.co/GbFfeB2Euw

Cancer and TNF inhibitors Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions https://t.co/MzksmSEUjf https://t.co/dxCIHxL1gc

Watch: SpA Insights: New Therapies https://t.co/01wwJIkmRJ https://t.co/tMJufATzyd